- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01373515
Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
Phase 1 Study of Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
Study Overview
Status
Intervention / Treatment
Detailed Description
DCPrime is testing an allogeneic (non-self cells, standardised product) DC-based immunotherapy in cancer patients. The technology consists of sustainable dendritic progenitor cells (named "DCOne™") and a proprietary method to expand these and to create functional mature dendritic cells (DCP-001).
AML is a fast growing form of leukemia that particularly in the elderly (>60) is life threatening. As age is an important factor in determining the success of AML treatment, overall, AML has a bad prognosis as only 24% of the patients are alive 5 years after diagnosis.
Without treatment AML is fatal, usually within months. Chemotherapy can cure patients and prolong survival in responders; however, chemotherapy is also quite toxic and can cause substantial morbidity and mortality. The most commonly prescribed first line therapy for patients with AML is a combination of an anthracycline and cytarabine; in the Western world the anthracycline is either daunorubicin or idarubicin. Post remission therapy (consolidation therapy) is usually given.
There is therefore substantial medical need for new treatment modalities. One of the major difficulties regarding development of new agents is that relatively low response rates and toxicity issues have been in the way of approval of new agents. Immunotherapy, in particular with the therapeutic vaccines, is expected to have potential in prevention of recurrence of disease after cytoreductive therapy. Any drug that could prevent or reduce minimal residual disease in the population is likely to meet a strong medical need for this population of high risk patients.
In this phase 1 trial consecutive eligible patients will be treated until 12 patients have completed the study. Patients will be started with the vaccination program within 2 months after having achieved complete remission or in patients who have stable disease over at least a 2 month period.
The first cohort (n=3) will receive 4 bi-weekly vaccinations of 1x10E7 DCP-001, the second cohort (n=3) will receive 4 bi-weekly vaccinations of 2.5x10E7 DCP-001, and the last cohort (n=3) will receive 4 bi-weekly vaccinations of 5x10E7 DCP-001. The Dose Limiting Toxicity (DTL) is defined as non-hematological toxicity of ≥ 3 according to common toxicity criteria v3.0. The 4th cohort (matched for HLA-A2) will receive 4 vaccinations of the highest dose (5x10E7 DCP-001) or, in case this turned out to be toxic (as determined by the vaccination profile of cohort 1, 2 and 3), this group will receive the Maximum Tolerated Dose (MTD).
DCP-001 vaccine is presented as a direct injectable sterile cell suspension consisting of irradiated mature dendritic cells in cryopreservation solution packed in vials. The vaccine will be administered intradermally.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- VU University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with AML, in second complete remission of AML (all FAB-subclasses), not eligible for additional intensification therapies e.g. allogeneic (allo) PSCT [independent of age]; OR
- Patients with relapse (smouldering) AML not eligible for additional intensification therapies e.g. alloPSCT; OR
- Patients with de novo (smouldering) AML not eligible for intensive treatment according to current HOVON trials.
- Patients >65 years of age with de novo AML in first CR and off protocol of current HOVON trials.
- WHO performance of 0, 1, or 2.
- Male or female patients at least 18 years of age and <80 years by date of enrolment.
- Patients not treated within current HOVON or other AML trials.
- Ability and willingness to give informed consent.
- HLA-A2.1 positive patients (only for cohort 4).
Exclusion Criteria:
- Uncontrolled active infection.
- Previous immunotherapy in last 3 months (except for anti-CD33 targeted therapy).
- Previous allogeneic PSCT.
- Inadequate bone marrow function: absolute neutrophile count (ANC) < 0.5x10E9/L, or platelet count < 20x10E9/L or active bleeding with platelet count > 20x10E9/L.
Inadequate liver function, defined as:
- Serum (total) bilirubin > 1.5 x the upper limit of normal (ULN)
- AST/SGOT or ALT/SGPT > 2.5 x ULN
- Alkaline phosphatase levels > 2.5 times the ULN at baseline.
Inadequate renal function, defined as:
- Serum creatinine > 1.5 x ULN
- Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
- Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start.
- Women of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly).
- Major surgical procedure (including open biopsy) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
- Minor surgical procedures, within 24 hours prior to the first study treatment.
- Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (i.e. active) cardiovascular disease: cerebrovascular accident (CVA) / stroke within ≤ 6 months prior to the first study treatment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia requiring medication.
- Known hypersensitivity to any of the study drugs or excipients.
- Evidence of an other medical condition (such as psychiatric illness, physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
- Eligibility for the HOVON-93 study (intensification program ± allogeneic stem cell transplant).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1; 1x10E7 DCP-001
n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
|
4 bi-weekly vaccinations
|
Experimental: Cohort 2; 2.5x10E7 DCP-001
n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
|
4 bi-weekly vaccinations
|
Experimental: Cohort 3; 5x10E7 DCP-001
n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
|
4 bi-weekly vaccinations
|
Experimental: Cohort 4; 5x10E7 DCP-001
n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
|
4 bi-weekly vaccinations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/Feasibility of DCP-001 vaccination
Time Frame: three months and follow up after study completion
|
The primary endpoint of this study will be the safety and feasibility of DCP-001 vaccination in AML patients.
Safety will be assessed by means of laboratory evalulations, lhysical examination, vital sign assessments and adverse events recording.
Clinical efficacy is assessed by the presence of leukemic cells in blood and bonemarrow and physical examination at baseline, during and after vaccination
|
three months and follow up after study completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological responses induced by DCP-001 vaccination
Time Frame: 3 months
|
The secondary endpoint of this study will be establishment of immunological responses induced by DCP-001 vaccination.
|
3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DCOne-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia (AML)
-
Goethe UniversityCompleted
-
Daiichi Sankyo, Inc.CompletedAMLUnited States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
-
Gemin XCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingNewly Diagnosed Acute Myeloid Leukemia (AML)China
-
Zhejiang ACEA Pharmaceutical Co. Ltd.Recruiting
-
German Cancer Research CenterUniversity Hospital Heidelberg; University Hospital DresdenNot yet recruitingRelapsed/Refractory Acute Myeloid Leukemia (AML)Germany
-
Georgetown UniversityNational Heart, Lung, and Blood Institute (NHLBI); Jazz PharmaceuticalsRecruitingAcute Myeloid Leukemia (AML) in RemissionUnited States
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | AML Stage, AdultChina
Clinical Trials on DCP-001
-
MendusAmsterdam UMC, location VUmcActive, not recruitingAcute Myeloid Leukemia in RemissionNorway, Netherlands, Sweden, Finland, Germany
-
University Medical Center GroningenMendusRecruiting
-
Weill Medical College of Cornell UniversityNational Institute on Aging (NIA)Not yet recruitingDyadic Family Caregiver-person With Dementia Online InterventionUnited States
-
District Headquarters Teaching Hospital SahiwalCompletedTransverse Fracture of Shaft of TibiaPakistan
-
Assiut UniversityRecruitingOpen Type III (A&B)Pediatric and Adolescent Tibial Shaft Fractures | Ilizarov FixationEgypt
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Terminated
-
Stanford UniversityViFIVE Inc.RecruitingKnee Osteoarthritis | Shoulder Adhesive CapsulitisUnited States
-
Isfahan University of Medical SciencesCompletedTibial Shaft FractureIran, Islamic Republic of
-
Rockefeller UniversityCompletedMelanoma | Neoplasm MetastasisUnited States
-
Oslo University HospitalCompletedCoronary Artery Disease | Decision MakingNorway